# Pacritinib vs. Hydroxyurea in Advanced Proliferative Chronic Myelomonocytic Leukemia

> **NCT07033598** · PHASE2 · RECRUITING · sponsor: **Theradex** · enrollment: 66 (estimated)

## Conditions studied

- Leukemia, Myelomonocytic, Chronic

## Interventions

- **DRUG:** Pacritinib
- **DRUG:** Hydroxyurea

## Key facts

- **NCT ID:** NCT07033598
- **Lead sponsor:** Theradex
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-01
- **Primary completion:** 2028-07
- **Final completion:** 2028-12
- **Target enrollment:** 66 (ESTIMATED)
- **Last updated:** 2026-03-05

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07033598

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07033598, "Pacritinib vs. Hydroxyurea in Advanced Proliferative Chronic Myelomonocytic Leukemia". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT07033598. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*